AbbVie to Invest $380 Million in Chicago to Further Expand US API Manufacturing

robot
Abstract generation in progress

AbbVie announced a new $380 million investment to build two advanced active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago campus. These facilities, expected to be operational in 2029, will utilize AI and advanced manufacturing to support next-generation neuroscience and obesity medications, strengthening AbbVie’s US manufacturing capabilities. This investment contributes to AbbVie’s $100 billion commitment to US R&D and capital investments over the next decade, following recent plans to expand API manufacturing and acquire a device manufacturing facility in Arizona.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin